Summary
The episode works through what the nine-point difference between arms in the MAPP2 trial measures, why the placebo-with-therapy arm improved by almost fifteen points, and why effect sizes from waitlist-controlled psychotherapy trials cannot be set beside the MAPP results. Sarah and Kiffer use the MAPP2 blinding survey to calculate how large an expectancy effect would have to be to explain the whole difference, and they discuss why beliefs recorded at the end of a trial are an imperfect measure of expectancy. They then review, from statements by MAPS and reporting by CBC News, how the safeguards at a Vancouver trial site failed to protect a participant, and they appraise a hypothetical protocol excerpt as a research ethics board would. The hosts close by debating whether a narrow access route for people whose PTSD has not responded to other treatments is defensible before further trials, and they agree that any access should carry the evidence collection and protections that the trials lacked.